Appendix B. Sources of evidence considered by the Committee

Appendix B. Sources of evidence considered by the Committee

A. The Assessment Report for this appraisal was prepared by Centre for Reviews and Dissemination, University of York.

King S, Riemsma R, Drummond M et al. A systematic review of the clinical and cost-effectiveness of methylphenidate hydrochloride, dexamfetamine sulphate and atomoxetine for attention deficit hyperactivity disorder (ADHD) in children and adolescents, December 2004.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, Assessment Report and the Appraisal Consultation Document (ACD). Consultee organisations are provided with the opportunity to appeal against the Final Appraisal Determination.

I) Manufacturers/sponsors:

  • Celltech Group Plc

  • Cephalon (UK)

  • Eli Lilly and Company

  • Janssen-Cilag Ltd

  • Rubio Laboratorios S.A.

II) Professional/specialist and patient/carer groups:

  • ADDERS

  • Barnardo's

  • National Attention Deficit Disorder Information and Support Service

  • Neonatal & Paediatric Pharmacists Group

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Psychiatrists

  • Royal Pharmaceutical Society

  • The Paediatric Psychopharmacology Group

  • Young Minds

  • Department of Health

  • Welsh Assembly Government

III) Commentator organisations (without the right of appeal):

  • National Collaborating Centre for Mental Health

  • NHS Quality Improvement for Scotland

  • National Public Health Service for Wales

C. The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Ms Andrea Bilbow, Founder and Director, National Attention Deficit Disorder Information and Support Service

  • Mr Mike Heimann, Clinical Nurse Specialist, Child and Adolescent Mental Forum

  • Mrs Jenny Missen, Chairperson, ADDISS and Hounslow and Spelthorne Parents' Support Group

  • Ms Jackie O'Connell, Consultant Nurse for ADHD, East Sussex County Healthcare NHS Trust

  • Ms Noreen Ryan, Nurse Consultant, Royal Bolton Hospital

  • Professor Eric Taylor, Head of Department, Child & Adolescent Psychiatry, Institute of Psychiatry, Kings College London